On this episode of Stock Movers:
- Him & Hers (HIMS) shares surge after Novo Nordisk was said to have ended its public feud with the company with an agreement to sell its weight-loss drugs on the Hims platform. Novo and Hims plan to announce a new partnership as soon as Monday, according to a person familiar with the matter, who spoke on the condition of anonymity.
- Live Nation Entertainment (LYV) shares rise. Live Nation Entertainment Inc. and its Ticketmaster subsidiary have reached a settlement with federal antitrust authorities, according to the Justice Department. The agreement was announced with no details provided, but it would reportedly open parts of Live Nation's ticketing arm to third-party sellers and make it easier for other promoters to put on shows at amphitheaters that Live Nation controls.
- Brown-Forman (BF/B) shares fall after Bernstein analyst Nadine Sarwat cut her recommendation on the alcohol beverage company to market perform from outperform. “This rating change isn’t about the structural vs. cyclical debate in US alcohol or the risk of price wars (from the US ‘whiskey glut’ or competitors) — our views on this remain unchanged,” Sarwat writes.
On this episode of Stock Movers:
- Him & Hers (HIMS) shares surge after Novo Nordisk was said to have ended its public feud with the company with an agreement to sell its weight-loss drugs on the Hims platform. Novo and Hims plan to announce a new partnership as soon as Monday, according to a person familiar with the matter, who spoke on the condition of anonymity.
- Live Nation Entertainment (LYV) shares rise. Live Nation Entertainment Inc. and its Ticketmaster subsidiary have reached a settlement with federal antitrust authorities, according to the Justice Department. The agreement was announced with no details provided, but it would reportedly open parts of Live Nation's ticketing arm to third-party sellers and make it easier for other promoters to put on shows at amphitheaters that Live Nation controls.
- Brown-Forman (BF/B) shares fall after Bernstein analyst Nadine Sarwat cut her recommendation on the alcohol beverage company to market perform from outperform. “This rating change isn’t about the structural vs. cyclical debate in US alcohol or the risk of price wars (from the US ‘whiskey glut’ or competitors) — our views on this remain unchanged,” Sarwat writes.
See omnystudio.com/listener for privacy information.
